


PHARMACEUTICAL 2017



Seres Therapeutics Inc. Rank 124 of 313





PHARMACEUTICAL 2017



Seres Therapeutics Inc. Rank 124 of 313

The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Seres Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is -110%, being 307% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	198,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,457
Liabilities, Non-Current	0
Other Assets	38,152
Other Compr. Net Income	-179
Other Expenses	0
Other Liabilities	109,558
Other Net Income	1,260
Property and Equipment	36,125
Research and Development	81,989
Revenues	21,766
Selling, General and Administrative Expense	32,616

Output Variable	Value in 1000 USD
Assets	272,646
Liabilities	140,015
Expenses	114,605
Stockholders Equity	132,631
Net Income	-91,579
Comprehensive Net Income	-91,668
Economic Capital Ratio	-110%